OBJECTIVE: The aim of this study was to evaluate the efficiency of photodynamic therapy (PDT) with phenotiazinium compounds (methylene blue and toluidine blue) and excitation by a non-coherent light source (RL50) to treat AIDS-related Kaposi's sarcoma (Sk-AIDS). BACKGROUND DATA: Sk-AIDS is a malignant disease that is recurrent in AIDS patients. Laser-based PDT protocols have been applied to treat Sk-AIDS with relative success. METHODS: A single patient with multiple lesions who had undergone chemotherapy without success was treated with several applications of PDT, and the patient was closely evaluated. The PDT protocol consisted of injecting a mixture of phenotiazinium compounds into the lesions and applying RL50 at 18 J/cm(2). RESULTS: Complete remission with excellent cosmetic result was observed. This result was discussed in terms of the known mechanisms of PDT action and compared with other PDT protocols. CONCLUSION: This inexpensive PDT protocol, which is based on phenothiazinium compounds and RL50, is efficient to treat Sk-AIDS.
OBJECTIVE: The aim of this study was to evaluate the efficiency of photodynamic therapy (PDT) with phenotiazinium compounds (methylene blue and toluidine blue) and excitation by a non-coherent light source (RL50) to treat AIDS-related Kaposi's sarcoma (Sk-AIDS). BACKGROUND DATA: Sk-AIDS is a malignant disease that is recurrent in AIDSpatients. Laser-based PDT protocols have been applied to treat Sk-AIDS with relative success. METHODS: A single patient with multiple lesions who had undergone chemotherapy without success was treated with several applications of PDT, and the patient was closely evaluated. The PDT protocol consisted of injecting a mixture of phenotiazinium compounds into the lesions and applying RL50 at 18 J/cm(2). RESULTS: Complete remission with excellent cosmetic result was observed. This result was discussed in terms of the known mechanisms of PDT action and compared with other PDT protocols. CONCLUSION: This inexpensive PDT protocol, which is based on phenothiazinium compounds and RL50, is efficient to treat Sk-AIDS.
Authors: Omar Mertins; Isabel O L Bacellar; Fabrice Thalmann; Carlos M Marques; Maurício S Baptista; Rosangela Itri Journal: Biophys J Date: 2014-01-07 Impact factor: 4.033
Authors: Yolanda Gilaberte; Carmen Aspiroz; M Carmen Alejandre; Elena Andres-Ciriano; Blanca Fortuño; Luis Charlez; Maria Jose Revillo; Michael R Hamblin; Antonio Rezusta Journal: Photomed Laser Surg Date: 2013-12-13 Impact factor: 2.796
Authors: Ellen M McDonagh; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2013-09 Impact factor: 2.089
Authors: Luisa De Sordi; M Adil Butt; Hayley Pye; Darina Kohoutova; Charles A Mosse; Gokhan Yahioglu; Ioanna Stamati; Mahendra Deonarain; Sinan Battah; Derren Ready; Elaine Allan; Peter Mullany; Laurence B Lovat Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240